keyword
MENU ▼
Read by QxMD icon Read
search

Solid tumor oncology

keyword
https://www.readbyqxmd.com/read/28536029/specific-humoral-and-cellular-immune-responses-in-cancer-patients-undergoing-chronic-immunization-with-a-vegf-based-therapeutic-vaccine
#1
Yanelys Morera, Javier Sánchez, Mónica Bequet-Romero, Katty-Hind Selman-Housein, Ana de la Torre, Francisco Hernández-Bernal, Yenima Martín, Acralys Garabito, Jesús Piñero, Cimara Bermúdez, Josué de la Torre, Marta Ayala, Jorge V Gavilondo
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, tolerance, and immunogenicity of CIGB-247 was studied in patients with advanced solid tumors at three antigen dose level. Surviving individuals of this clinical trial were eligible to receive off-trial voluntary re-immunizations...
May 20, 2017: Vaccine
https://www.readbyqxmd.com/read/28534144/coordination-of-care-in-survivorship-after-treatment-of-hematological-malignancies-the-journey-is-not-over-yet
#2
REVIEW
Catherine J Lee, Lori S Muffly
The number of adult survivors of hematologic malignancies is steadily growing. This population is at moderate to high risk for cancer survivorship issues including physical and psychosocial sequelae of intensive cancer therapies. Although cancer survivorship is a growing field in pediatric and solid tumor oncology, survivorship care and research has often been overlooked in the hematologic malignancies. In this review, we focus specifically on survivorship issues related to adult patients with hematologic malignancies and provide commentary on the role of cancer survivorship, proposed survivorship care models, and the economic and health policy obstacles associated with moving the cancer survivorship field forward in this very important patient population...
May 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28532763/nanomaterial-enabled-cancer-therapy
#3
REVIEW
Sabina Quader, Kazunori Kataoka
While cancer remains the major cause of death worldwide, nanomaterial (NM)-based diagnosis and treatment modalities are showing remarkable potential to better tackle clinical oncology by effectively targeting therapeutic agents to tumors. NMs can selectively accumulate in solid tumors, and they can improve the bioavailability and reduce the toxicity of encapsulated cytotoxic agents. Additional noteworthy functions of NMs in cancer treatment include the delivery of contrast agents to image tumor sites, delivery of genetic materials for gene therapy, and co-delivery of multiple agents to achieve combination therapy or simultaneous diagnostic and therapeutic outcomes...
May 19, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28526081/comprehensive-detection-of-germline-variants-by-msk-impact-a-clinical-diagnostic-platform-for-solid-tumor-molecular-oncology-and-concurrent-cancer-predisposition-testing
#4
Donavan T Cheng, Meera Prasad, Yvonne Chekaluk, Ryma Benayed, Justyna Sadowska, Ahmet Zehir, Aijazuddin Syed, Yan Elsa Wang, Joshua Somar, Yirong Li, Zarina Yelskaya, Donna Wong, Mark E Robson, Kenneth Offit, Michael F Berger, Khedoudja Nafa, Marc Ladanyi, Liying Zhang
BACKGROUND: The growing number of Next Generation Sequencing (NGS) tests is transforming the routine clinical diagnosis of hereditary cancers. Identifying whether a cancer is the result of an underlying disease-causing mutation in a cancer predisposition gene is not only diagnostic for a cancer predisposition syndrome, but also has significant clinical implications in the clinical management of patients and their families. METHODS: Here, we evaluated the performance of MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) in detecting genetic alterations in 76 genes implicated in cancer predisposition syndromes...
May 19, 2017: BMC Medical Genomics
https://www.readbyqxmd.com/read/28507203/immunotherapy-for-head-and-neck-squamous-cell-carcinoma-a-review-of-current-and-emerging-therapeutic-options
#5
REVIEW
Jessica M Moskovitz, Jennifer Moy, Tanguy Y Seiwert, Robert L Ferris
Advances in the field of cancer immunotherapy have occurred rapidly over the past decade. Exciting results from clinical trials have led to new treatment options and improved survival for patients with a myriad of solid tumor pathologies. However, questions remain unanswered regarding duration and timing of therapy, combination regimens, appropriate biomarkers of disease, and optimal monitoring of therapeutic response. This article reviews emerging immunotherapeutic agents and significant clinical trials that have led to advancements in the field of immuno-oncology for patients with head and neck squamous cell carcinoma...
May 15, 2017: Oncologist
https://www.readbyqxmd.com/read/28506521/role-of-imaging-in-response-assessment-and-individualised-treatment-for-sarcomas
#6
H Choi
The first systematic response evaluation criteria were established by WHO, based on the tumor size changes shortly after the computed tomography (CT) technique became available to the daily practice. RECIST, a simplified version of WHO criteria, and its newer version, RECIST1.1 are the currently available international response evaluation criteria in solid tumors and remains based on tumor size changes. While the introduction of molecularly targeted drugs has significantly improved the survival in patient with sarcomas, the evaluation of tumor response has become more complicated...
May 12, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28503645/immune-checkpoint-inhibitors-an-innovation-in-immunotherapy-for-the-treatment-and-management-of-patients-with-cancer
#7
REVIEW
Jennifer Dine, RuthAnn Gordon, Yelena Shames, Mary Kate Kasler, Margaret Barton-Burke
Cancer survival rates are generally increasing in the United States. These trends have been partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an example of one of the newer strategies used to fight cancer, which primes or activates the immune system to produce antitumor effects. The first half of this review paper concisely describes the cell mechanisms that control antitumor immunity and the major immunotherapeutic strategies developed to target these mechanisms. The second half of the review discusses in greater depth immune checkpoint inhibitors that have recently demonstrated tremendous promise for the treatment of diverse solid tumor types, including melanoma, non-small cell lung cancer, and others...
April 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28493841/diagnostic-performance-of-gait-speed-g8-and-g8-modified-indices-to-screen-for-vulnerability-in-older-cancer-patients-the-prospective-pf-ec-cohort-study
#8
Frederic Pamoukdjian, Florence Canoui-Poitrine, Coralie Longelin-Lombard, Thomas Aparicio, Nathalie Ganne, Philippe Wind, Claudia Martinez-Tapia, Etienne Audureau, Georges Sebbane, Laurent Zelek, Elena Paillaud
BACKGROUND: The diagnostic performance of tools used to screen vulnerability in older cancer patients varies widely. We assessed the diagnostic performance of gait speed (GS) for assessing vulnerability in such patients. METHODS: All consecutive outpatients 65 years and older were referred for geriatric oncology assessment (GA) before a therapeutic decision between November 2013 and April 2016 in a bicentric observational and prospective cohort study. Vulnerability was defined as impaired score on at least one of the 6 domains of the GA...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28493760/exploration-of-the-asco-and-esmo-value-frameworks-for-antineoplastic-drugs
#9
Daniel J Becker, Daniel Lin, Steve Lee, Benjamin P Levy, Danil V Makarov, Heather T Gold, Scott Sherman
PURPOSE: In 2015, both ASCO and the European Society for Medical Oncology (ESMO) proposed frameworks to quantify the benefit of antineoplastic drugs in the face of rising costs. We applied these frameworks to drugs approved by the US Food and Drug Administration over the past 12 years and examined relationships between costs and benefits. METHODS: We searched FDA.gov for drugs that received initial approval for solid tumors from 2004 to 2015 and calculated the ASCO Net Health Benefit version 2016 (NHB16) and 2015 (NHB15) and the ESMO Magnitude of Clinical Benefit Scale scores for each drug...
May 11, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28479239/renal-mass-and-localized-renal-cancer-aua-guideline
#10
Steven Campbell, Robert G Uzzo, Mohamad E Allaf, Eric B Bass, Jeffrey A Cadeddu, Anthony Chang, Peter E Clark, Brian J Davis, Ithaar H Derweesh, Leo Giambarresi, Debra A Gervais, Susie L Hu, Brian R Lane, Bradley C Leibovich, Philip M Pierorazio
PURPOSE: This AUA Guideline focuses on evaluation/counseling and management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS/METHODS: Systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A/B/C (Strong/Moderate/Conditional Recommendations, respectively) with additional statements presented as Clinical Principles or Expert Opinions...
May 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28478879/tumor-lysis-syndrome-a-unique-solute-disturbance
#11
REVIEW
Penelope Z Strauss, Shannan K Hamlin, Johnny Dang
Tumor lysis syndrome (TLS) is a life-threatening disorder that is an oncologic emergency. Risk factors for TLS are well-known, but the current literature shows case descriptions of unexpected acute TLS. Solid tumors and untreated hematologic tumors can lyse under various circumstances in children and adults. International guidelines and recommendations, including the early involvement of the critical care team, have been put forward to help clinicians properly manage the syndrome. Advanced practice nurses may be in the position of triaging and initiating treatment of patients with TLS, and need a thorough understanding of the syndrome and its treatment...
June 2017: Nursing Clinics of North America
https://www.readbyqxmd.com/read/28475230/outcomes-of-a-pediatric-surgical-oncology-fellowship-in-a-pediatric-cancer-institution
#12
I Fernandez-Pineda, D Sanders, B N Rao, S J Shochat, A M Davidoff
Surgery plays an important role as part of the treatment plan in most children with malignant solid tumors in regards to initial biopsy, upfront resection, and delayed resection. Surgeons also play a critical role in the treatment of surgical complications that may arise during medical treatment. The pediatric surgical oncologist should be familiar with the current treatment guidelines, histology implications, chemotherapy and radiation side effects, tumor staging, and overall care of the child with cancer...
May 5, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28460200/caecal-leiomyoma-detected-by-whole-body-mri-in-a-patient-with-hodgkin-lymphoma-first-case-report
#13
D Albano, E Sinagra, C Patti, D Narese, A Agrusa, G Di Buono, D Raimondo, M Midiri, R Lagalla, M Galia
INTRODUCTION: Hodgkin Lymphoma (HL) is one of the most curable malignant diseases. Modern treatments, like the combined radiochemotherapy and stem cell transplantation, have increased the number of malignant disease survivors. However, HL survivors are at risk of long-term effects, including the development of solid tumors. Secondary neoplasms are a major cause of late morbidity and mortality following treatment for HL. CASE REPORT: We report the case of a male patient, treated for HL by chemotherapy, who developed a large leiomyoma of the cecum one year after the treatment...
January 2017: Il Giornale di Chirurgia
https://www.readbyqxmd.com/read/28455788/diagnosis-and-treatment-patterns-for-patients-with-leptomeningeal-metastasis-from-solid-tumors-across-europe
#14
Emilie Le Rhun, Roberta Rudà, Patrick Devos, Khê Hoang-Xuan, Dieta Brandsma, Pedro Pérez Segura, Riccardo Soffietti, Michael Weller
Leptomeningeal metastases are a late manifestation of systemic cancer which affects up to 10% of patients with solid tumors. Prognosis is poor, and overall survival at 1 year is only approximately 10%. Management depends mainly on general and neurological condition, primary tumor, and patterns of metastasis, notably absence or presence of concurrent systemic or solid brain metastases. Here we set out to characterize current practice patterns of diagnosis and treatment of patients with leptomeningeal metastasis in Europe...
April 28, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28453694/clinical-benefit-price-and-approval-characteristics-of-fda-approved-new-drugs-for-treating-advanced-solid-cancer-2000-2015
#15
A Vivot, J Jacot, J-D Zeitoun, P Ravaud, P Crequit, R Porcher
Background: Prices of anti-cancer drugs are skyrocking. We aimed to assess the clinical benefit of new drugs for treating advanced solid tumors at the time of their approval by the US Food and Drug Administration (FDA) and to search for a relation between price and clinical benefit of drugs. Materials and methods: We included all new molecular entities and new biologics for treating advanced solid cancer that were approved by the FDA between 2000 and 2015. The clinical benefit of drugs was graded based on FDA medical review of pivotal clinical trials using the 2016-updated of the American Society of Clinical Oncology Value Framework (ASCO-VF) and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28449393/a-phase-1-study-of-the-c-met-inhibitor-tivantinib-arq197-in-children-with-relapsed-or-refractory-solid-tumors-a-children-s-oncology-group-study-phase-1-and-pilot-consortium-trial-advl1111
#16
James I Geller, John P Perentesis, Xiaowei Liu, Charles G Minard, Rachel A Kudgus, Joel M Reid, Elizabeth Fox, Susan M Blaney, Brenda J Weigel
BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors. METHODS: Oral tivantinib capsules were administered twice daily with food, continuously in 28-day cycles. Dose levels 170, 200, and 240 mg/m(2) /dose were evaluated using a rolling-six design (Part A)...
April 27, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28448747/a-hierarchical-bayesian-design-for-randomized-phase-ii-clinical-trials-with-multiple-groups
#17
Jun Yin, Rui Qin, Daniel J Sargent, Charles Erlichman, Qian Shi
Enhanced knowledge of the biological and genetic basis of cancer is re-defining target population for new treatments. In oncology, potential targets for a new therapeutic agent often include various solid and hematologic malignancies that share common signaling pathways. New agents are often tested in multiple tumor types across which information can be borrowed. We propose a hierarchical Bayesian design (HBD) to simultaneously test a novel agent in multiple groups for randomized phase II clinical trials with binary endpoints...
April 27, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28442420/eggerthella-lenta-bacteremia-in-solid-tumor-cancer-patients-pathogen-or-witness-of-frailty
#18
Paul-Louis Woerther, Sami Antoun, Elisabeth Chachaty, Mansouria Merad
Eggerthella lenta is increasingly found in patients with severe comorbidities. Because oncologic patients are exposed to emerging pathogens, we aimed to describe the factors associated with E. lenta bacteremia in this immunosuppressed population. Oncology patients with blood cultures positive for E. lenta were retrospectively recorded from 2009 to 2015. Socio-demographic and medical/biological data as well as potential risk factors and mortality were recorded and analyzed. Twenty-three patients were included...
April 22, 2017: Anaerobe
https://www.readbyqxmd.com/read/28441372/assessing-response-of-high-grade-gliomas-to-immune-checkpoint-inhibitors
#19
Solmaz Sahebjam, Dexter G Stallworth, Sepideh Mokhtari, Nam D Tran, John A Arrington
BACKGROUND: Immunotherapeutic agents, especially checkpoint inhibitors, have emerged as the mainstay of therapy for several solid and hematological malignancies. These therapies are under investigation for the treatment of high-grade gliomas and brain metastases. METHODS: This article reviews the unique challenges encountered when evaluating changes on magnetic resonance imaging (MRI) of glioblastomas seen in response to immunotherapy and checkpoint inhibitors and how to effectively incorporate MRI findings into the response assessment of high-grade gliomas to these emerging therapies...
April 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28437204/drainage-percutaneous-endoscopic-gastrostomy-for-malignant-bowel-obstruction-in-gastrointestinal-cancers-prognosis-and-implications-for-timing-of-palliative-intervention
#20
Kerry-Ann Pinard, Tabitha N Goring, Barbara C Egan, Douglas J Koo
BACKGROUND: Malignant bowel obstruction (MBO) is a frequent complication in patients with advanced solid tumors. Palliative relief may be achieved by the use of a drainage percutaneous endoscopic gastrostomy (dPEG) tube, although optimal timing of placement remains unknown. OBJECTIVES: To determine median survival after diagnosis of MBO and dPEG placement, factors associated with worse survival in MBO, factors associated with receipt of dPEG, and association of timing of dPEG placement on survival...
February 16, 2017: Journal of Palliative Medicine
keyword
keyword
61413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"